Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
12 10 2021
Historique:
accepted: 05 08 2021
entrez: 25 9 2021
pubmed: 26 9 2021
medline: 5 10 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 pandemic, is one of the biggest threats to public health. However, the dynamic of SARS-CoV-2 infection remains poorly understood. Replication-competent recombinant viruses expressing reporter genes provide valuable tools to investigate viral infection. Low levels of reporter gene expressed from previous reporter-expressing recombinant (r)SARS-CoV-2 in the locus of the open reading frame (ORF)7a protein have jeopardized their use to monitor the dynamic of SARS-CoV-2 infection in vitro or in vivo. Here, we report an alternative strategy where reporter genes were placed upstream of the highly expressed viral nucleocapsid (N) gene followed by a porcine tescherovirus (PTV-1) 2A proteolytic cleavage site. The higher levels of reporter expression using this strategy resulted in efficient visualization of rSARS-CoV-2 in infected cultured cells and excised lungs or whole organism of infected K18 human angiotensin converting enzyme 2 (hACE2) transgenic mice. Importantly, real-time viral infection was readily tracked using a noninvasive in vivo imaging system and allowed us to rapidly identify antibodies which are able to neutralize SARS-CoV-2 infection in vivo. Notably, these reporter-expressing rSARS-CoV-2, in which a viral gene was not deleted, not only retained wild-type (WT) virus-like pathogenicity in vivo but also exhibited high stability in vitro and in vivo, supporting their use to investigate viral infection, dissemination, pathogenesis, and therapeutic interventions for the treatment of SARS-CoV-2 in vivo.

Identifiants

pubmed: 34561300
pii: 2111593118
doi: 10.1073/pnas.2111593118
pmc: PMC8521683
pii:
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
ORF7a protein, SARS-CoV-2 0
Viral Proteins 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141222
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI161175
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: J.-G.P., J.J.K., M.R.W., and L.M.-S. are coinventors on a patent that includes claims related to some of the NAbs described.

Références

J Virol. 2005 Dec;79(24):15511-24
pubmed: 16306622
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Biotechnol Genet Eng Rev. 2010;26:223-60
pubmed: 21415883
Cell Host Microbe. 2020 Jul 8;28(1):124-133.e4
pubmed: 32485164
J Vis Exp. 2019 Jun 24;(148):
pubmed: 31282877
Nature. 2021 Jan;589(7843):603-607
pubmed: 33166988
ACS Chem Biol. 2012 Nov 16;7(11):1848-57
pubmed: 22894855
PLoS Biol. 2021 Feb 25;19(2):e3001091
pubmed: 33630831
J Virol. 2021 Aug 10;95(17):e0040221
pubmed: 34133899
J Clin Virol. 2020 Aug;129:104523
pubmed: 32623351
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11531-6
pubmed: 20534532
Virus Res. 1995 May;36(2-3):119-30
pubmed: 7653093
Viruses. 2018 Nov 20;10(11):
pubmed: 30463334
Curr Protoc Microbiol. 2020 Dec;59(1):e126
pubmed: 33048448
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Nat Microbiol. 2021 Jan;6(1):73-86
pubmed: 33340034
J Virol. 2020 Sep 15;94(19):
pubmed: 32669332
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Cell Rep Med. 2021 Mar 16;2(3):100218
pubmed: 33649747
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
J Virol. 2021 Jan 11;:
pubmed: 33431557
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62
pubmed: 24043791
J Virol. 2019 May 1;93(10):
pubmed: 30867298
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Virus Res. 2020 Sep;286:198043
pubmed: 32502551
Cell Host Microbe. 2020 May 13;27(5):704-709.e2
pubmed: 32259477
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Virol. 2014 Sep;88(18):10525-40
pubmed: 24965472
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959

Auteurs

Chengjin Ye (C)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227; cye@txbiomed.org lmartinez@txbiomed.org.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Kevin Chiem (K)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Jun-Gyu Park (JG)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Jesus A Silvas (JA)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Desarey Morales Vasquez (D)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Julien Sourimant (J)

Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303.

Michelle J Lin (MJ)

Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA 98195.

Alexander L Greninger (AL)

Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA 98195.

Richard K Plemper (RK)

Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303.

Jordi B Torrelles (JB)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

James J Kobie (JJ)

Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294.

Mark R Walter (MR)

Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294.

Juan Carlos de la Torre (JC)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.

Luis Martinez-Sobrido (L)

Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX 78227; cye@txbiomed.org lmartinez@txbiomed.org.
Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH